1. Home
  2. ORIQ vs CYPH Comparison

ORIQ vs CYPH Comparison

Compare ORIQ & CYPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

ORIQ

Origin Investment Corp I Ordinary Shares

N/A

Current Price

$10.28

Market Cap

88.4M

Sector

N/A

ML Signal

N/A

CYPH

Cypherpunk Technologies Inc.

N/A

Current Price

$1.19

Market Cap

73.4M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
ORIQ
CYPH
Founded
2024
2011
Country
Singapore
United States
Employees
N/A
6
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
88.4M
73.4M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
ORIQ
CYPH
Price
$10.28
$1.19
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
49.5K
3.9M
Earning Date
01-01-0001
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$10.01
$0.50
52 Week High
$10.28
$3.70

Technical Indicators

Market Signals
Indicator
ORIQ
CYPH
Relative Strength Index (RSI) 66.74 57.67
Support Level $10.17 $0.86
Resistance Level N/A $1.30
Average True Range (ATR) 0.01 0.15
MACD 0.00 0.01
Stochastic Oscillator 100.00 55.51

Price Performance

Historical Comparison
ORIQ
CYPH

About ORIQ Origin Investment Corp I Ordinary Shares

Origin Investment Corp I is a blank check company.

About CYPH Cypherpunk Technologies Inc.

Cypherpunk Technologies Inc is a privacy technology company focused on implementing a digital asset treasury business anchored by Zcash, which is a cryptographic digital asset that operates on a decentralized, open-source blockchain network known as the Zcash Network. Through its subsidiary, the company is also engaged in developing novel therapies for patients with cancer. The group holds Zcash as part of its digital treasury business and has the following drug candidates under development in its biopharma business: Sirexatamab (DKN-01), a monoclonal antibody that inhibits Dickkopf-related protein 1, or DKK1; and a preclinical antibody program, FL-501, that is designed to treat cachexia-related indications.

Share on Social Networks: